Patents by Inventor Chixiang ZHANG

Chixiang ZHANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230181773
    Abstract: A visualizable radioactive carbon microsphere (CMS) suspension, a preparation method, and a use thereof are provided. Every 1 mL of the visualizable radioactive CMS suspension includes: CMS: 10 mg to 500 mg; a therapeutic radionuclide with an activity of 5 mCi to 500 mCi; an imaging radionuclide with an activity of 0.1 mCi to 100 mCi; a small organic molecule: 0 mg to 100 mg; and a first solution: 0.1 mL to 1.0 mL. The preparation method mainly includes a process of allowing the CMS to adsorb the small organic molecule, the therapeutic radionuclide, and the imaging zirconium [89Zr]. The visualizable radioactive CMS suspension can realize both local radiotherapy and real-time imaging of a solid tumor lesion, and thus achieves the visualized treatment of a tumor, which provides a new radioactive CMS product that integrates diagnosis and treatment.
    Type: Application
    Filed: April 23, 2021
    Publication date: June 15, 2023
    Applicant: CHENGDU NEW RADIOMEDICINE TECHNOLOGY CO., LTD.
    Inventors: Xiaosheng ZHAO, Jun ZHANG, Chixiang ZHANG, Jing LU, Qiangqiang LIU, Xianjin LUO, Wenliang MA, Qiang GE, Jiming CAI
  • Publication number: 20230149570
    Abstract: A metal nuclide-loaded carbon microsphere (CMS), and a preparation method and a use thereof are provided. The preparation method includes: subjecting a metal ion and a small organic molecule to a reaction in an aqueous solution to obtain a complex; allowing a CMS to adsorb the complex; and subjecting the CMS adsorbing the complex to a first treatment. The metal nuclide-loaded CMS prepared by the method can stably exist in an aqueous solution at a temperature of lower than 180° C. and a pressure of lower than 10 MPa and has a metal nuclide dissolution rate of lower than 0.1% in the aqueous solution. After the prepared metal nuclide-loaded CMS is subjected to moist-heat sterilization at 121° C. for 15 min, a radionuclide release rate is still lower than 0.1%, which can significantly reduce the safety risk of the radioactive microsphere product in clinical use.
    Type: Application
    Filed: April 23, 2021
    Publication date: May 18, 2023
    Applicant: CHENGDU NEW RADIOMEDICINE TECHNOLOGY CO., LTD.
    Inventors: Xiaosheng ZHAO, Chixiang ZHANG, Jing LU, Jun ZHANG, Zhuoming LI, Shuang ZHANG, Xianjin LUO, Dongmei LI, Xuezheng HU, Qiang GE, Maoliang LI, Jiming CAI